GSK (LON:GSK) Earns Underweight Rating from JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating reaffirmed by JPMorgan Chase & Co. in a report issued on Monday, LSE.Co.UK reports.

A number of other brokerages also recently commented on GSK. Shore Capital restated a “buy” rating on shares of GSK in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($25.22) target price on shares of GSK in a research note on Friday, June 28th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 ($27.16) price target on shares of GSK in a research report on Thursday, June 27th. Barclays reiterated an “equal weight” rating and set a GBX 1,725 ($22.31) price target on shares of GSK in a research report on Tuesday, May 7th. Finally, Citigroup lowered their price target on GSK from GBX 2,120 ($27.42) to GBX 1,900 ($24.57) and set a “buy” rating on the stock in a research report on Friday, July 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 1,820 ($23.54).

GSK Stock Performance

Shares of GSK traded up GBX 1 ($0.01) during mid-day trading on Monday, reaching GBX 1,554 ($20.10). The company had a trading volume of 57,148,012 shares, compared to its average volume of 7,685,522. GSK has a 52-week low of GBX 1,330.19 ($17.20) and a 52-week high of GBX 1,823.50 ($23.58). The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. The stock has a market capitalization of £63.40 billion, a P/E ratio of 1,429.36, a PEG ratio of 1.19 and a beta of 0.27. The stock has a 50 day moving average of GBX 1,600.46 and a two-hundred day moving average of GBX 1,637.30.

Insider Activity

In other news, insider Wendy Becker bought 446 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were acquired at an average price of GBX 1,614 ($20.87) per share, for a total transaction of £7,198.44 ($9,309.93). Company insiders own 1.60% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.